Editorial Oncomology Platform and Utility Protocols (Q11677): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: EU contribution (P835): 1,592,180.4524 euro) |
(Changed an Item: Fixing rounding issue) |
||||||||||||||
| Property / EU contribution | |||||||||||||||
1,592,180.45 Euro
| |||||||||||||||
| Property / EU contribution: 1,592,180.45 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / EU contribution: 1,592,180.45 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / EU contribution: 1,592,180.45 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
Revision as of 09:34, 22 September 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Editorial Oncomology Platform and Utility Protocols |
Project in Czech Republic financed by DG Regio |
Statements
39,804,511.31 Czech koruna
0 references
61,769,881.0 Czech koruna
0 references
64.44 percent
0 references
31 October 2020
0 references
Institute of Applied Biotechnologies a.s.
0 references
50°5'1.93"N, 14°30'28.48"E
0 references
10800
0 references
10800
0 references
Jedná se o projekt vysoké technologické úrovně a vysoké míry inovace, který si klade za cíl významně zvýšit produktový potenciál společnosti Institute of Applied Biotechnologies a.s. (IAB) ve spolupráci s výzkumným partnerem Lékařskou fakultou Univerzity Palackého v Olomouci, jmenovitě Ústavem molekulární a translační medicíny (UMTM). Cílem je vývoj produktů pro prediktivní onkologickou diagnostiku založenou na cirkulujících buňkách / DNA / RNA. a. (Czech)
0 references
It is a project of high technological level and a high level of innovation which aims to significantly increase the product potential of the Institute of Applied Biotechnologies a.s. (IAB) in cooperation with the research partner of the Faculty of Medicine of Palacký University in Olomouc, namely the Institute of Molecular and Translation Medicine (UMTM). The objective is the development of products for predictive cancer diagnostics, based on circulating cell cells/DNA/RNA. a. (English)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/17_107/0012422
0 references